These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 26279520

  • 21. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature.
    Ferguson NN, Thomas CP, Hohl RJ, Syrbu SI, Stone MS, Wanat KA.
    Am J Dermatopathol; 2015 Oct; 37(10):790-4. PubMed ID: 25747810
    [Abstract] [Full Text] [Related]

  • 22. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 23. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 24. Immunotherapy for Epstein-Barr virus-associated malignancies.
    Long HM, Parsonage G, Fox CP, Lee SP.
    Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
    [Abstract] [Full Text] [Related]

  • 25. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
    Montone KT, Hodinka RL, Salhany KE, Lavi E, Rostami A, Tomaszewski JE.
    Mod Pathol; 1996 Jun; 9(6):621-30. PubMed ID: 8782198
    [Abstract] [Full Text] [Related]

  • 26. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma.
    Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, Berger F, Delecluse HJ.
    Lancet; 2003 Jan 18; 361(9353):217-23. PubMed ID: 12547545
    [Abstract] [Full Text] [Related]

  • 27. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 18; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 28. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM, Krams SM.
    Transplantation; 2017 Sep 18; 101(9):2009-2016. PubMed ID: 28376031
    [Abstract] [Full Text] [Related]

  • 29. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M, Granai M, Bonzheim I, Steinhilber J, Schittenhelm J, Bethge W, Quintanilla-Martinez L, Fend F, Federmann B.
    Virchows Arch; 2021 Jun 18; 478(6):1135-1148. PubMed ID: 33324999
    [Abstract] [Full Text] [Related]

  • 30. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P, ESCMID Study Group of Infection in Compromised Hosts.
    Clin Microbiol Infect; 2014 Sep 18; 20 Suppl 7():109-18. PubMed ID: 24475976
    [Abstract] [Full Text] [Related]

  • 31. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus.
    Han SB, Bae EY, Lee JW, Jang PS, Lee DG, Chung NG, Jeong DC, Cho B, Lee SJ, Kang JH, Kim HK.
    Int J Hematol; 2014 Aug 18; 100(2):188-99. PubMed ID: 24981711
    [Abstract] [Full Text] [Related]

  • 32. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
    Ann Hematol; 2006 Jul 18; 85(7):478-84. PubMed ID: 16586109
    [Abstract] [Full Text] [Related]

  • 33. bcl-2 protein is strongly expressed in post-transplant lymphoproliferative disorders.
    Chetty R, Biddolph S, Kaklamanis L, Cary N, Stewart S, Giatromanolaki A, Gatter K.
    J Pathol; 1996 Nov 18; 180(3):254-8. PubMed ID: 8958801
    [Abstract] [Full Text] [Related]

  • 34. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
    Tanner JE, Alfieri C.
    Transpl Infect Dis; 2001 Jun 18; 3(2):60-9. PubMed ID: 11395971
    [Abstract] [Full Text] [Related]

  • 35. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR, Nalesnik MA, Swerdlow SH.
    Am J Surg Pathol; 2006 Dec 18; 30(12):1604-12. PubMed ID: 17122518
    [Abstract] [Full Text] [Related]

  • 36. Epstein-Barr virus latent and replicative gene expression in post-transplant lymphoproliferative disorders and AIDS-related non-Hodgkin's lymphomas. French Study Group of Pathology for HIV-associated Tumors.
    Rea D, Delecluse HJ, Hamilton-Dutoit SJ, Marelle L, Joab I, Edelman L, Finet JF, Raphael M.
    Ann Oncol; 1994 Dec 18; 5 Suppl 1():113-6. PubMed ID: 8172807
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.